entertainment -WSS

entertainment

author：fashion 2025-09-05 03:01:38 - browse：4

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout Newsletter: Bluebird, CVS, Contineum

focus

knowledge

WSS

Creating egg and sperm cells from stem cells raises ethical issues

White House drug shortages task force keeps mum with Congress

Faced with fears of OxyContin misuse, sales reps touted its safety

Nurses recount patients attacks

Timeline: Special counsel's investigation into Trump's handling of classified documents

Virtual Event: March of the Biosimilars

hotspot

entertainment

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Physicians and social media: If you see something, say something?

Activists slam private health insurers over coverage restrictions

CDC overhauls leadership of center that led response to Covid

Activists slam private health insurers over coverage restrictions

CDC overhauls leadership of center that led response to Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Plastic surgeons increase patient psychiatric screenings

Medical leaders decry Supreme Court decision on affirmative action

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

hotspot

Timeline: Special counsel's investigation into Trump's handling of classified documents

Kim Kardashian sparks debate on benefits of full

SCOTUS questions limit to govt efforts to fight misinformation

CDC overhauls leadership of center that led response to Covid

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Neuroscience’s long legacy of racism

focus

knowledge

leisure time

knowledge